文献速递头颈外科咽喉与嗓音

喉鳞状细胞癌的治疗延迟:国家癌症数据库分析

Treatment delays in laryngeal squamous cell carcinoma: A national cancer database analysis.
PubMed 文献 · Laryngoscope · 2018-05-14

该研究基于国家癌症数据库2004至2013年33,819例成人喉鳞状细胞癌患者,计算诊断至治疗开始、手术至辅助治疗、放疗时长、总治疗包和诊断至治疗结束的间隔,分析延迟与患者、肿瘤和治疗因素及总生存的关联。结果显示手术患者中位间隔分别为28、42、48、91和107天,非手术患者诊断至治疗开始、放疗和诊断至治疗结束中位间隔为33、50和85天;种族和保险状态与多数间隔延迟相关,学术和高容量机构放疗延迟较少但其他间隔延迟增加;手术至放疗和总治疗包延迟与手术患者总生存相关,诊断至治疗开始和诊断至治疗结束延迟与非手术患者总生存相关,放疗延迟与两组总生存均相关。结论认为这些时长可作为国家基准,延迟可作为喉鳞癌的质量指标。

要点

  • 手术患者中位诊断至治疗开始28天,手术至放疗42天,放疗48天,总治疗包91天,诊断至治疗结束107天。
  • 非手术患者中位诊断至治疗开始33天,放疗50天,诊断至治疗结束85天。
  • 放疗延迟与手术和非手术患者总生存均相关(HR=1.21和1.37)。

核心结论

  • 这些治疗间隔时长可作为喉鳞状细胞癌的国家基准,治疗延迟可考虑作为质量指标。

研究设计与样本

  • 回顾性队列研究,纳入国家癌症数据库2004至2013年33,819例成人喉鳞状细胞癌患者。

主要发现

  • 手术患者中位诊断至治疗开始、手术至放疗开始、放疗、总治疗包和诊断至治疗结束分别为28、42、48、91和107天。
  • 非手术患者中位诊断至治疗开始、放疗和诊断至治疗结束分别为33、50和85天。
  • 种族和保险状态与多数间隔延迟相关;学术和高容量机构放疗延迟较少但多数其他间隔延迟增加。

临床怎么用

  • 可将研究中各治疗间隔的中位时长作为喉鳞状细胞癌治疗及时性的国家基准。
  • 关注手术至放疗、总治疗包、诊断至治疗开始、诊断至治疗结束及放疗延迟,尤其非手术患者的诊断至治疗相关延迟。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To characterize treatment delays in laryngeal cancer and associate delays with patient, tumor, and treatment factors and with overall survival. METHODS: We identified 33,819 adults with laryngeal squamous cell carcinoma (LSCC) in the National Cancer Database from 2004 to 2013. We calculated durations of diagnosis-to-treatment initiation, surgery-to-adjuvant treatment, radiotherapy duration, total treatment package, and diagnosis-to-treatment end intervals. Delays were associated with patient, tumor, and treatment characteristics via multivariable logistic regression and with overall survival by Cox proportional hazards regression. RESULTS: Median durations of diagnosis-to-treatment initiation, surgery-to-radiation initiation, radiation treatment, total treatment package, and diagnosis-to-treatment end were 28, 42, 48, 91, and 107 days in surgical patients; median durations of diagnosis-to-treatment initiation, radiation treatment, and diagnosis-to-treatment end were 33, 50, and 85 days in nonsurgical patients. Race and insurance status were linked to delays in most intervals. Academic and high-volume facilities had less delayed radiation treatment but increased delays in most other intervals. Delayed surgery-to-radiation and total treatment package intervals were associated with overall survival in surgical patients (hazard ratio [HR] = 1.15 [1.03-1.29], P = 0.015; HR = 1.16 [1.02-1.31], P = 0.025). Diagnosis-to-treatment initiation and diagnosis-to-treatment end intervals were associated with overall survival in nonsurgical patients (HR = 1.08 [1.02-1.14], P = 0.007; HR = 1.09 [1.03-1.16], P = 0.003, respectively) but not in surgical patients (HR = 0.96 [0.87-1.06] P = 0.440; HR = 1.13 [0.99-1.29], P = 0.062). Radiation delays were associated with overall survival in surgical and nonsurgical patients (HR = 1.21 [1.09-1.36], P = 0.001; HR = 1.37 [1.30-1.44], P < 0.001). CONCLUSION: These durations can serve as national benchmarks. Delays could be considered quality indicators in LSCC. LEVEL OF EVIDENCE: 2b Laryngoscope, 128:2751-2758, 2018.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Morse E, Fujiwara RJT, Judson B, et al. Treatment delays in laryngeal squamous cell carcinoma: A national cancer database analysis. Laryngoscope. 2018. PMID: 29756382. doi:10.1002/lary.27247

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。